The benefits of using GenAI in drug discovery and preclinical development

April 26, 2024

Remove from favorites

Add to favorites

The article discusses the potential benefits of utilizing generative artificial intelligence (GenAI) in drug discovery and preclinical development. It emphasizes how GenAI can reform the drug discovery process by creating novel molecules, reducing costs, and accelerating timelines.

Key areas where GenAI can address drug discovery issues include target identification, target validation, hit generation, and lead optimization.

Furthermore, GenAI can aid in preclinical testing, study design, administrative automation, and regulatory submissions. The text highlights the expected impact of GenAI on cost reduction across different phases of drug development, with forecasts indicating significant savings.

Additionally, it explores considerations for organizations to implement GenAI effectively, including strategies for adoption, change management, governance, and potential opportunities for various stakeholders in the pharmaceutical industry.